ARISE - Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
Enrolling By Invitation
18-99 years
All
Phase
3
5 participants needed
1 Location
Brief description of study
The purpose is to validate patient-reported outcomes questionnaire subjects given ALIS (amikacin liposome inhalation suspension) as part of a study treatment regimen for NontuberculousMycobacterial (NTM) Lung Infection.
It will also evaluate the safety and efficacy of the study treatments with ALIS, azithromycin, and ethambutol. Targeted population is patients newly diagnosed with NontuberculousMycobacterial (NTM) Lung Infection.
Procedures include: questionnaires, physical exams, vital signs, audiology and spirometry testing, actigraphy, lab samples, and sputum collection.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Mycobacterium avium Complex,Mycobacterium avium
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
22 Aug 2024.
Study ID: 844687
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
